ArticleEndocrine connections2017
The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome.
Article in Endocrine connections, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- Statins for women with polycystic ovary syndrome not actively trying to conceive.The Cochrane database of systematic reviews · 2023Pooled it
- Effect of atorvastatin on testosterone levels.The Cochrane database of systematic reviews · 2021Pooled it
- Exploring the comorbidity of type 2 diabetes mellitus and polycystic ovary syndrome: treatment with traditional Chinese medicine.Frontiers in medicine · 2026Review
- Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis.Frontiers in pharmacology · 2025Article
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS.International journal of molecular sciences · 2020Review
- A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.Therapeutic advances in endocrinology and metabolism · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an increased risk of developing T2DM in women with polycystic ovary syndrome (PCOS), and there is evidence that statins improve metabolic parameters in these patients. However, there are some data to show that statins increase the risk of incipient diabetes. MATERIALS AND
methodsWe have previously shown that 12 weeks of atorvastatin improves insulin resistance when measured using HOMA-IR. This
resultsThere was a significant reduction in HOMA-β (240 ± 3.2 vs 177 ± 2.3;
conclusionTreatment with atorvastatin for 12 weeks in women with PCOS significantly reduced HOMA-β. This could be potentially due to fall in β-cell requirement with improvement of insulin resistance rather than a reduction of β-cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.